CA Patent

CA3085116C — Treatment of circadian rhythm disorders

Assigned to Vanda Pharmaceuticals Inc · Expires 2022-07-19 · 4y expired

What this patent protects

ABSTRACT Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. Date Recue/Date Receive…

USPTO Abstract

ABSTRACT Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. Date Recue/Date Received 2020-06-30

Drugs covered by this patent

Patent Metadata

Patent number: CA3085116C
Jurisdiction: CA
Classification: —
Expires: 2022-07-19
Drug substance claim: No
Drug product claim: No
Assignee: Vanda Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.